Furthermore, <i>ex vivo</i> treatment of primary AML cells reduced proliferation, highlighting potential clinical applicability.<h4>Conclusion</h4>These findings suggest that Visomitin exerts potent anti-leukemic effects by simultaneously promoting differentiation and apoptosis through ROS-mediated SYK inhibition. This evidence concerns the gene SYK and acute myeloid leukemia.